Skip to main content

PharmaEngine, Incorporated has received approval from the U.S. Food and Drug Administration for an investigational new drug (IND) application submitted for the investigative agent PEP02 (liposome irinotecan injection) in the treatment of pancreatic cancer.

PEP02 is an encapsulated liposomal formulation of irinotecan hydrochloride (Camptosar®). Although still in early trials, PEP02—either alone or in combination with other chemotherapy agents—has demonstrated improved pharmacokinetic, safety, and efficacy profiles compared with other formulations of irinotecan.

PharmaEngine plans to enroll patients with pancreatic cancer who have failed Gemzar® (gemcitabine) to a Phase II trial evaluating PEP02 in 2009.

Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.